Skip to main content

Cannabinoide und Immunsystem

Menschen, Mäuse und Zellen

Cannabinoids and the immune system

Of men, mice and cells

Der Schmerz volume 18, pages 203–210 (2004)Cite this article

Zusammenfassung

Der Einsatz von Cannabinoiden oder Cannabis in der Medizin wird kontrovers diskutiert. Derzeit sind nur Einzelsubstanzen (Dronabinol, Nabilone®) zur Symptomkontrolle in der Palliativmedizin zugelassen.

Das physiologische Cannabinoidsystem mit den spezifischen Rezeptoren CB1 und CB2 und seinen endogenen Liganden moduliert u.a. Appetit, Schmerzverarbeitung und immunologische Prozesse. Die befürchtete Immunsuppression durch Cannabinoide ließ sich beim Menschen bisher jedoch nicht sicher nachweisen. Lediglich Marijuanarauchen verminderte die bakteriziden Funktionen humaner Alveolarmakrophagen.

Nur im Tierversuch kam es zu verringerter zellulärer Immunität mit stärkerem Tumorwachstum und gehäuften Virusinfekten. In-vitro-Studien zeigten eine Suppression aller Immunzellen, jedoch nur bei Cannabinoidkonzentrationen weit oberhalb pharmakologischer Plasmaspiegel. Zusammenfassend ist eine klinisch relevante Immunsuppression bei der Therapie mit den verfügbaren oralen Cannabinoiden nicht wahrscheinlich, bei anderen Applikationsformen (Inhalation) könnten durchaus lokal immunsuppressive Effekte auftreten.

Abstract

The medical use of cannabis or cannabinoid compounds is controversial. Cannabinoids like the Δ9-THC (tetrahydrocannabinol) or the synthetic derivative Nabilone are available against cancer- and HIV-associated cachexia, nausea and vomiting. Over the last 20 years, the cannabinoid receptors CB1 and CB2 and their endogenous ligands have been found. The involvement of this endogenous cannabinoid signalling system in feeding, appetite, pain perception and immunomodulation could be demonstrated using animal and in vitro studies. Thus, the concern about immunosuppressive effects in humans using medical cannabinoid preparations grew. However, up to now most human studies have failed to demonstrate a well-defined and reproducible immunosuppressive cannabinoid-effect. Only the smoking of marijuana showed a significant local immunosuppression of the bactericidal activity of human alveolar macrophages.

In animal studies, cannabinoids were identified as potent modulators of cytokine production, causing a shift from Th1 to Th2 cytokines. In consequence, a compromised cellular immunity was observed in these animals, resulting in enhanced tumor growth and reduced immunity to viral infections. In vitro, immunosuppressive effects were shown in all immune cells, but only at high micromolar cannabinoid concentrations not reached under normal clinical conditions. In conclusion, there is no evidence that cannabinoids induce a serious, relevant immunosuppression in humans, with the exception of marijuana-smoking which may affect local brocho-alveolar immunity.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5.

Literatur

  1. Baldwin GC, Tashkin DP, Buckley DM et al. (1997) Habitual smoking of marijuana and cocaine impairs alveolar macrophage function and cytokine production. J Resp Crit Care Med 156: 1606–1613

    Google Scholar 

  2. Baczynsky WO, Zimmerman AM (1983) Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. I. In vivo investigation of the primary and secondary immune response. Pharmacology 26: 1–11

    Google Scholar 

  3. Berdyshev EV (2000) Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108: 169–190

    Google Scholar 

  4. Bredt BM, Higuera-Alhino D, Shade SB, et al. (2002) Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 42: 82–89

    Google Scholar 

  5. Bouaboula M, Rinaldi M, Carayon P et al. (1993) Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214: 173–180

    Google Scholar 

  6. Cabral GA, Lockmuller JC, Mishkin LM (1986) Delta 9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc Soc Exp Biol Med 181: 305–311

    Google Scholar 

  7. Carayon P, Marchand J, Dussossoy D et al. (1998) Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors During B-Cell Differentiation. Blood 92: 3605–3615

    Google Scholar 

  8. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2: 69–82

    Google Scholar 

  9. Chang YH, Lee ST, Lin WW (2001) Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 81: 715–723

    Google Scholar 

  10. Condie R, Herring A, Koh WS, Lee M, Kaminski NE (1996) Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271: 13175–13183

    Google Scholar 

  11. Derocq JM, Segui M, Marchand J, Le Fur G, Casellas P (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369: 177–182

    Google Scholar 

  12. Djeu JY, Wand M, Friedmann H (1991) Adverse effect of Δ9-tetrahydrocannabinol on human neutrophil function. Adv Exp Med Biol 288: 57–62

    Google Scholar 

  13. Friedmann H, Klein TW, Newton C, Daaka Y (1995) Marijuana, receptors and immunomodulation. Adv Exp Med Biol 373: 103–113

    Google Scholar 

  14. Gupta S, Grieco MH, Cushman P (1974) Impairment of rosette-forming T lymphocytes in chronic marijuana smokers. New Engl J Med 291: 874–876

    Google Scholar 

  15. Juel-Jensen BE (1972) Cannabis and recurrent herpes simplex. BMJ 835: 296

    Google Scholar 

  16. Klein TW, Friedman H (1990) Modulation of murine immune cell function by marijuana components. In: RR Watson (ed) Drugs of abuse and immune function. CRC Press, Boca Raton, pp 87–111

  17. Klein TW, Newton C, Widen R, Friedmann H (1993) Δ9-Tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 267: 451–466

    Google Scholar 

  18. Klein TW, Newton C, Friedmann H (1998) Cannabinoid receptors and immunity. Immunol Today 18: 373–381

    Google Scholar 

  19. Klein TW, Lane B, Newton CA, Friedmann H (2000) The cannabinoid system and the cytokine network. Proc Soc Exp Biol Med 225: 1–8

    Google Scholar 

  20. Kraft B, Wintersberger W, Kress HG (2003) Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide. (Submitted)

  21. Massi P, Fuzio D, Vigano D, Sacerdote P, Parolaro D (2000) Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer cell activity. Eur J Pharmacol 387: 343–347

    Google Scholar 

  22. Mishkin EM, Cabral GA (1985) Delta9-Tetrahydrocannabinol decreases host resistance to Herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol 66: 2539–2549

    Google Scholar 

  23. Morahan PS, Klykken PC, Smith SH, Harris LS, Munson AE (1979) Effects of cannabinoids on host resistance to Listeria monocytogenes and Herpes simplex virus. Infect Immun 23: 670–674

    Google Scholar 

  24. Nahas GG, Suciu-Foca N, Armand J-P, Morishima A (1974) Inhibition of cellular mediated immunity in marijuana smokers. Science 183: 419–420

    Google Scholar 

  25. Nakano Y, Pross S, Friedman H (1993a) Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages. Life Sci 52: 41–51

    Google Scholar 

  26. Newton C, Klein TW, Friedman H (1998) The role of macrophages in THC-induced alteration of the cytokine network. Adv Exp Med Biol 437: 207–214

    Google Scholar 

  27. Newton CA, Klein TW, Friedmann H (1994) Secondary immunity to Legionella pneumophila and TH1 activity are suppressed by Δ9-tetrahydrocannabinol-injection. Infect Immun 62: 4015–4020

    Google Scholar 

  28. Rachelefski GS, Opelz G, Mickey MR et al. (1976) Intact humoral and cell-mediated immunity in chronic marijuana smoking. J Allergy Clin Immunol 58: 483–490

    Google Scholar 

  29. Sacerdote P, Massi P, Panerai AE, Parolaro D (2000) In: vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 109: 155–163

    Google Scholar 

  30. Sanchez C, Velasco G, Guzman M (1997) Metabolic stimulation of mouse spleen lymphocytes by low doses of delta 9-tetrahydrocannabinol. Life Sci 60: 1709–1717

    Google Scholar 

  31. Shrivastava MD, Shrivastava BI, Brouhard B (1998) Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40: 179–185

    Google Scholar 

  32. Specter S, Lancz G, Goodfellow D (1991) Suppression of human macrophage function by Δ9-tetrahydrocannabinol. J Leukocyte Biol 50: 423–426

    Google Scholar 

  33. Specter S, Lancz G (1991) Effects of marijuana on natural killer cell activity. In: Friedman H, Specter S, Klein TW (Eds) Drugs of Abuse Immunity and Immunodeficiency. Plenum, New York, pp 47–56

  34. Specter S, Rivenbark M, Newton C, Kawakami Y, Lancz G (1989) Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2. Int J Immunopharmacol 11: 63–69

    Google Scholar 

  35. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42: 71–81

    Google Scholar 

  36. Wallace JM, Tashkin DP, Oishi JS, Barbers RG (1988) Peripheral blood lymphocyte subpopulations and mitogen responsiveness in tobacco and marijuana smokers. J Psychoactive Drugs 20: 9–14

    Google Scholar 

  37. West JP, Lysle DP, Dykstra LA (1997) Tolerance development to morphine-induced alterations of immune status. Drug Alcohol Depend 46: 147–157

    Google Scholar 

  38. White SC, Brin SC, Janicki BW (1975) Mitogen-induced blastogenic responses of lymphocytes from marijuana smokers. Science 188: 71–72

    Google Scholar 

  39. Yea SS, Yang KH, Kaminski NE (2000) Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther 292: 597–605

    Google Scholar 

  40. Zhu LX, Sharma S, Stolina M et al. (2000) Delta-9-tetrahydrocannabinol inhibits anti-tumor immunity by a CB2 receptor mediated, cytokine dependent pathway. J Immunol 165: 373–380

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Anästhesie und Allgemeine Intensivmedizin (B), Medizinische Universität/AKH Wien, Wien

    B. Kraft & H. G. Kress

  2. Abteilung für Anästhesie und Allgemeine Intensivmedizin (B), Medizinische Universität/AKH Wien, Währinger Gürtel 18–20, 1090 , Wien, Österreich

    B. Kraft

Authors
  1. B. Kraft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. G. Kress
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Kraft.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kraft, B., Kress, H.G. Cannabinoide und Immunsystem. Schmerz 18, 203–210 (2004). https://doi.org/10.1007/s00482-003-0245-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00482-003-0245-7

Schlüsselwörter

  • Cannabinoide
  • Immunsystem
  • Immunsuppression

Keywords

  • Cannabinoids
  • Immune system
  • Immunosuppression